Atriva Therapeutics announces first closing of series A financing round

03.01.2019 Atriva Therapeutics announces first closing of series A financing round

Funds to advance antiviral lead product ATR-002 into clinical trials

Atriva Therapeutics, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the first closing in its ongoing series A financing round lead by Meneldor and High-Tech Gründerfonds GmbH (HTGF). The Company founders and management joined the round, also. These funds will be focused to prepare first-in-humans clinical testing of the Company’s lead product candidate ATR-002, to be started in 2019. ATR-002 is a first-in-class host-targeting inhibitor of viral replication in influenza and other respiratory infections, an important area of high unmet medical need. The Company will secure additional series A funds for the Phase I and Phase II development of ATR-002 through proof of concept trials.

During 2018, Atriva Therapeutics successfully completed preclinical development of ATR-002 and recently filed a request for scientific advice from a European regulatory authority to provide guidance on the executed preclinical development program and the planned ATR-002 Phase I study in healthy volunteers.

The Company is now advancing ATR-002 towards full clinical development, focusing on patients with influenza at high risk of developing complications. ATR-002 is a MEK inhibitor, targeting a fundamental cellular protein of the replication pathway of influenza-causing viruses and other respiratory viral infections. MEK inhibitors have shown high potential as efficacious and safe antiviral drugs to address the need for a novel, broadly active and resistance-avoiding influenza therapy.

“This first closing is a strong show of support for our novel host-targeting approch in influenza therapy and is a very encouraging signal for the ongoing series A financing round. We are excited that our technology is attracting great interest among potential partners and leading specialist venture capital firms,” said Dr. Rainer Lichtenberger, co-founder and CEO of Atriva Therapeutics. “Clinical trial preparations are ongoing, and we look forward to the next important milestones in the validation of our unique therapeutic approach.”

Source: https://www.atriva-therapeutics.com/news/84-first-closing-series-a

Contact:
Atriva Therapeutics GmbH
Dr. Rainer Lichtenberger, CEO
phone: +49 7071 859 7673, mobile: +49 173 743 1897
lichtenberger [at] atriva-therapeutics.com

Media and Investor Relations:
MC Services AG
Raimund Gabriel / Eva Bauer
phone: +49 (0)89 21022880
atriva-therapeutics [at] mc-services.eu